292 related articles for article (PubMed ID: 11507208)
21. HIV-1 dual/mixed tropic isolates show different genetic and phenotypic characteristics and response to maraviroc in vitro.
Svicher V; Balestra E; Cento V; Sarmati L; Dori L; Vandenbroucke I; D'Arrigo R; Buonomini AR; Van Marck H; Surdo M; Saccomandi P; Mostmans W; Aerssens J; Aquaro S; Stuyver LJ; Andreoni M; Ceccherini-Silberstein F; Perno CF
Antiviral Res; 2011 Apr; 90(1):42-53. PubMed ID: 21349294
[TBL] [Abstract][Full Text] [Related]
22. HIV co-receptors as targets for antiviral therapy.
Schols D
Curr Top Med Chem; 2004; 4(9):883-93. PubMed ID: 15134547
[TBL] [Abstract][Full Text] [Related]
23. Hemofiltrate CC chemokine 1[9-74] causes effective internalization of CCR5 and is a potent inhibitor of R5-tropic human immunodeficiency virus type 1 strains in primary T cells and macrophages.
Münch J; Ständker L; Pöhlmann S; Baribaud F; Papkalla A; Rosorius O; Stauber R; Sass G; Heveker N; Adermann K; Escher S; Klüver E; Doms RW; Forssmann WG; Kirchhoff F
Antimicrob Agents Chemother; 2002 Apr; 46(4):982-90. PubMed ID: 11897579
[TBL] [Abstract][Full Text] [Related]
24. Agonist-induced internalization of CC chemokine receptor 5 as a mechanism to inhibit HIV replication.
Ferain T; Hoveyda H; Ooms F; Schols D; Bernard J; Fraser G
J Pharmacol Exp Ther; 2011 Jun; 337(3):655-62. PubMed ID: 21389095
[TBL] [Abstract][Full Text] [Related]
25. Differential activation of CC chemokine receptors by AOP-RANTES.
Elsner J; Mack M; Brühl H; Dulkys Y; Kimmig D; Simmons G; Clapham PR; Schlöndorff D; Kapp A; Wells TN; Proudfoot AE
J Biol Chem; 2000 Mar; 275(11):7787-94. PubMed ID: 10713092
[TBL] [Abstract][Full Text] [Related]
26. Enhancement of human immunodeficiency virus type 1 infection by the CC-chemokine RANTES is independent of the mechanism of virus-cell fusion.
Gordon CJ; Muesing MA; Proudfoot AE; Power CA; Moore JP; Trkola A
J Virol; 1999 Jan; 73(1):684-94. PubMed ID: 9847374
[TBL] [Abstract][Full Text] [Related]
27. Coreceptor ligand inhibition of fetal brain cell infection by HIV type 1.
Hibbitts S; Reeves JD; Simmons G; Gray PW; Epstein LG; Schols D; de Clercq E; Wells TN; Proudfoot AE; Clapham PR
AIDS Res Hum Retroviruses; 1999 Jul; 15(11):989-1000. PubMed ID: 10445811
[TBL] [Abstract][Full Text] [Related]
28. Inhibitory effects of small-molecule CCR5 antagonists on human immunodeficiency virus type 1 envelope-mediated membrane fusion and viral replication.
Takashima K; Miyake H; Furuta RA; Fujisawa JI; Iizawa Y; Kanzaki N; Shiraishi M; Okonogi K; Baba M
Antimicrob Agents Chemother; 2001 Dec; 45(12):3538-43. PubMed ID: 11709336
[TBL] [Abstract][Full Text] [Related]
29. Inhibition of human immunodeficiency virus replication by a dual CCR5/CXCR4 antagonist.
Princen K; Hatse S; Vermeire K; Aquaro S; De Clercq E; Gerlach LO; Rosenkilde M; Schwartz TW; Skerlj R; Bridger G; Schols D
J Virol; 2004 Dec; 78(23):12996-3006. PubMed ID: 15542651
[TBL] [Abstract][Full Text] [Related]
30. TAK-652 inhibits CCR5-mediated human immunodeficiency virus type 1 infection in vitro and has favorable pharmacokinetics in humans.
Baba M; Takashima K; Miyake H; Kanzaki N; Teshima K; Wang X; Shiraishi M; Iizawa Y
Antimicrob Agents Chemother; 2005 Nov; 49(11):4584-91. PubMed ID: 16251299
[TBL] [Abstract][Full Text] [Related]
31. Medicinal chemistry applied to a synthetic protein: development of highly potent HIV entry inhibitors.
Hartley O; Gaertner H; Wilken J; Thompson D; Fish R; Ramos A; Pastore C; Dufour B; Cerini F; Melotti A; Heveker N; Picard L; Alizon M; Mosier D; Kent S; Offord R
Proc Natl Acad Sci U S A; 2004 Nov; 101(47):16460-5. PubMed ID: 15545608
[TBL] [Abstract][Full Text] [Related]
32. Two mechanisms for human immunodeficiency virus type 1 inhibition by N-terminal modifications of RANTES.
Pastore C; Picchio GR; Galimi F; Fish R; Hartley O; Offord RE; Mosier DE
Antimicrob Agents Chemother; 2003 Feb; 47(2):509-17. PubMed ID: 12543651
[TBL] [Abstract][Full Text] [Related]
33. Novel reporter T-cell line highly susceptible to both CCR5- and CXCR4-using human immunodeficiency virus type 1 and its application to drug susceptibility tests.
Miyake H; Iizawa Y; Baba M
J Clin Microbiol; 2003 Jun; 41(6):2515-21. PubMed ID: 12791875
[TBL] [Abstract][Full Text] [Related]
34. R5 and X4 HIV envelopes induce distinct gene expression profiles in primary peripheral blood mononuclear cells.
Cicala C; Arthos J; Martinelli E; Censoplano N; Cruz CC; Chung E; Selig SM; Van Ryk D; Yang J; Jagannatha S; Chun TW; Ren P; Lempicki RA; Fauci AS
Proc Natl Acad Sci U S A; 2006 Mar; 103(10):3746-51. PubMed ID: 16505369
[TBL] [Abstract][Full Text] [Related]
35. Amino-terminally modified RANTES analogues demonstrate differential effects on RANTES receptors.
Proudfoot AE; Buser R; Borlat F; Alouani S; Soler D; Offord RE; Schröder JM; Power CA; Wells TN
J Biol Chem; 1999 Nov; 274(45):32478-85. PubMed ID: 10542293
[TBL] [Abstract][Full Text] [Related]
36. The LD78beta isoform of MIP-1alpha is the most potent CC-chemokine in inhibiting CCR5-dependent human immunodeficiency virus type 1 replication in human macrophages.
Aquaro S; Menten P; Struyf S; Proost P; Van Damme J; De Clercq E; Schols D
J Virol; 2001 May; 75(9):4402-6. PubMed ID: 11287590
[TBL] [Abstract][Full Text] [Related]
37. Human immunodeficiency virus type 1 entry inhibitors selected on living cells from a library of phage chemokines.
Hartley O; Dorgham K; Perez-Bercoff D; Cerini F; Heimann A; Gaertner H; Offord RE; Pancino G; Debré P; Gorochov G
J Virol; 2003 Jun; 77(12):6637-44. PubMed ID: 12767983
[TBL] [Abstract][Full Text] [Related]
38. Donor- and ligand-dependent differences in C-C chemokine receptor 5 reexpression.
Sabbe R; Picchio GR; Pastore C; Chaloin O; Hartley O; Offord R; Mosier DE
J Virol; 2001 Jan; 75(2):661-71. PubMed ID: 11134280
[TBL] [Abstract][Full Text] [Related]
39. Mode of coreceptor use by R5 HIV type 1 correlates with disease stage: a study of paired plasma and cerebrospinal fluid isolates.
Karlsson U; Antonsson L; Repits J; Medstrand P; Owman C; Kidd-Ljunggren K; Hagberg L; Svennerholm B; Jansson M; Gisslén M; Ljungberg B
AIDS Res Hum Retroviruses; 2009 Dec; 25(12):1297-1305. PubMed ID: 20001314
[TBL] [Abstract][Full Text] [Related]
40. Analyses of anti-HIV type 1 activity of a small CCR5 peptide antagonist.
Wang FY; He SY; Zhang ZJ; He LF; Chen XW; Teng T
AIDS Res Hum Retroviruses; 2011 Oct; 27(10):1111-5. PubMed ID: 21375388
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
